¼¼°èÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå
Sulphonamides
»óǰÄÚµå : 1784173
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 291 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼³Æù¾Æ¹Ìµå ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 6,250¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 2,590¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼³Æù¾Æ¹Ìµå ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 4.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 6,250¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®µÇ°í ÀÖ´Â ºÎ¹® Áß ÇϳªÀÎ °æ±¸Á¦´Â CAGR 4.9%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 250¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±¹¼Ò ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,430¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 8.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀåÀº 2024³â¿¡´Â 3,430¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 3,360¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 8.0%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.7%¿Í 3.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¼³Æù¾Æ¹Ìµå ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

÷´Ü Ç×»ýÁ¦ ½Ã´ë¿¡µµ ¼³Æù¾Æ¹Ìµå°¡ Áß¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî?

»õ·Î¿î Á¾·ùÀÇ Ç×»ýÁ¦°¡ µîÀåÇϰí ÀÖÀ½¿¡µµ ºÒ±¸Çϰí, ¼³Æù¾Æ¹Ìµå´Â ±¤¹üÀ§ÇÑ È°¼º, Àú·ÅÇÑ °¡°Ý, ÀÔÁõµÈ ÀÓ»óÀû ÀÌ·Â µîÀ¸·Î ÀÎÇØ Àü ¼¼°è Ç×±ÕÁ¦ Ä¡·áÀÇ ±âº» ¿ä¼Ò·Î ³²¾ÆÀÖ½À´Ï´Ù. °¡Àå ÃʱâÀÇ ÇÕ¼º Ç×±ÕÁ¦ÀÎ ¼³Æù¾Æ¹Ìµå´Â ¿ä·Î °¨¿°°ú È£Èí±âÁúȯ¿¡¼­ ¾È±¸ °¨¿°°ú ¼ö¸·¿°¿¡ À̸£±â±îÁö ¼¼±Õ °¨¿°ÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ¾î ¿Ô½À´Ï´Ù. ¼³Æù¾Æ¹ÌµåÀÇ Áö¼ÓÀûÀÎ ÀÇÀÇ´Â ¾à¸®ÇÐÀû ´Ù¾ç¼º°ú ƯÈ÷ ½Å¾à¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑµÈ Áö¿ª¿¡¼­ ƯÁ¤ ¹ÚÅ׸®¾Æ ±ÕÁÖ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ È¿°ú¿¡ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼³Æù¾Æ¹Ìµå´Â ÀϹÝÀûÀ¸·Î Æ®¸®¸ÞÅäÇÁ¸²°ú °°Àº ´Ù¸¥ Ç×±ÕÁ¦¿Í º´¿ëÇÏ¿© Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ³»¼º±ÕÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ¼³Æù¾Æ¹ÌµåÀÇ »ç¿ëÀº Àΰ£ÀÇ ÀǾàǰ¿¡ ±¹ÇѵÇÁö ¾Ê½À´Ï´Ù. ¼³Æù¾Æ¹Ìµå´Â ƯÈ÷ °¡ÃàÀ̳ª °¡±Ý·ù¿Í °°Àº ¼öÀÇÇÐ ºÐ¾ß¿¡¼­µµ ¼¼±Õ °¨¿°À» °ü¸®ÇÏ°í ½Äǰ ¾ÈÀü¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â Áúº´ÀÇ ¹ß»ýÀ» ¿¹¹æÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ, ¼³Æù¾Æ¹Ìµå´Â ºñ¿ë È¿À²ÀûÀ̱⠶§¹®¿¡ ƯÈ÷ ¼±Áø Ä¡·á¹ý¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇÑÀûÀÎ ÁßÀú¼Òµæ ±¹°¡¿¡¼­ °øÁߺ¸°Ç ÇÁ·Î±×·¥¿¡ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. Àΰ£°ú µ¿¹°ÀÇ °Ç°­¿¡ Àû¿ëµÉ ¼ö Àֱ⠶§¹®¿¡ ¾ÈÁ¤ÀûÀÎ ¼ö¿äÀÇ ±âÁؼ±ÀÌ È®º¸µÇ¾î ¼¼°è ÇコÄÉ¾î ½Ã½ºÅÛ¿¡¼­ Àå±âÀûÀÎ À¯¿ë¼ºÀÌ ´õ¿í °­Á¶µÇ°í ÀÖ½À´Ï´Ù.

Ç×±ÕÁ¦ ³»¼º(AMR)Àº ¼³Æù¾Æ¹Ìµå ½ÃÀå¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

Àü ¼¼°èÀûÀ¸·Î Ç×±ÕÁ¦ ³»¼º(AMR)ÀÇ Áõ°¡´Â ¼³Æù¾Æ¹Ìµå ½ÃÀå¿¡ ÀÌÁßÀ¸·Î ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ÇÑÆíÀ¸·Î´Â ÀϹÝÀûÀÎ º´¿ø±ÕÀÇ ³»¼ºÈ­·Î ÀÎÇØ ¼³Æù¾Æ¹Ìµå¸¦ Æ÷ÇÔÇÑ ¿À·¡µÈ Ç×»ýÁ¦¿¡ ´ëÇÑ ÀçÆò°¡°¡ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ÀϺΠÀÓ»ó ÇöÀå, ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ ±¹°¡¿¡¼­´Â ³»¼º±ÕÀÇ Áõ°¡¸¦ ¸·±â À§ÇØ Ä¡·áÁ¦¸¦ ¼øÈ¯Çϰųª º´¿ëÇÏ´Â Ç×±ÕÁ¦ ½ºÆ©¾îµå½Ê Àü·«ÀÇ ÀÏȯÀ¸·Î ¼³Æù¾Æ¹Ìµå°¡ Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ´Ù½Ã µµÀԵǰí ÀÖ½À´Ï´Ù. ÇÑÆí, AMR¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁö¸é¼­ Àΰ£°ú ¼öÀÇÇÐ ¸ðµÎ¿¡¼­ Ç×»ýÁ¦ »ç¿ë¿¡ ´ëÇÑ ±ÔÁ¦°¡ °­È­µÇ¾î ¼³Æù¾Æ¹ÌµåÀÇ Ã³¹æ ¹× Åõ¿© ¹æ¹ý¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. °¨½Ã ÇÁ·Î±×·¥¿¡¼­´Â Ç×»ýÁ¦ »ç¿ë ÇöȲÀ» »ó¼¼È÷ ÃßÀûÇÒ °ÍÀ» ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀϺΠ±¹°¡¿¡¼­´Â ȯ°æ ³ëÃâ°ú ±³Â÷ ³»¼ºÀ» Á¦ÇÑÇϱâ À§ÇØ ³ó¾÷¿¡¼­ ¼³Æù¾Æ¹ÌµåÀÇ ¿¹¹æÀû »ç¿ëÀ» Á¦ÇÑÇϰųª ´Ü°èÀûÀ¸·Î ÆóÁöÇÏ·Á´Â ¿òÁ÷ÀÓÀ» º¸À̰í ÀÖ½À´Ï´Ù. ±×·¯³ª ¼³Æù¾Æ¹Ìµå´Â ½ÅÁßÇÏ°Ô »ç¿ëÇÑ´Ù¸é Ç×±ÕÁ¦ÀÇ Áß¿äÇÑ µµ±¸ÀÓ¿¡´Â º¯ÇÔÀÌ ¾ø½À´Ï´Ù. Ç¥Àû ¾à¹° ¹æÃâ, ³ª³ëÀÔÀÚ Ä³¸®¾î µî »õ·Î¿î Á¦Çü ¹× Àü´Þ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ¿¬±¸µµ À¯È¿¼º Çâ»ó°ú ³»¼º À§Çè °¨¼Ò¸¦ ¸ñÇ¥·Î ÁøÇà ÁßÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁøÈ­ÇÏ´Â »óȲ ¼Ó¿¡¼­ ½ÃÀå ȯ°æÀº ÁøºÎÈ­º¸´Ù´Â Àü ¼¼°è AMR ¿ÏÈ­ ³ë·Â¿¡ µû¶ó °ü¸®µÈ Áõ°Å ±â¹Ý ¾ÖÇø®ÄÉÀ̼ÇÀÇ Çʿ伺¿¡ ÀÇÇØ À籸¼ºµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀÇ ¾ÈÁ¤¼º¿¡ À־ µ¿¹°¿ë ÀǾàǰ°ú ³ó¾÷¿ëÀǾàǰÀº ¾î¶² ¿ªÇÒÀ» ÇÒ ¼ö ÀÖÀ»±î?

µ¿¹°¿ë ÀǾàǰ°ú ³ó¾÷¿ë ÀǾàǰÀº ¼³Æù¾Æ¹ÌµåÀÇ ¼¼°è ¼ö¿ä¸¦ À¯ÁöÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. µ¿¹°¿ë ÀǾàǰ¿¡¼­ ¼³Æù¾Æ¹Ìµå´Â Ä۽õãÁõ, »ì¸ð³Ú¶óÁõ, È£Èí±âÁúȯ µî °¡Ãà, °¡±Ý·ù, ¾ç½Ä¾÷ÀÇ ¼¼±Õ¼º °¨¿°ÁõÀ» Ä¡·áÇÏ´Â µ¥ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±¤¹üÀ§ÇÑ ½ºÆåÆ®·³ Ȱ¼ºÀ» °¡Áö°í ÀÖ°í »ó´ëÀûÀ¸·Î Àú·ÅÇϱ⠶§¹®¿¡ Áý¾àÀûÀÎ Ãà»ê ½Ã½ºÅÛ, ƯÈ÷ Ãà»êÀÌ ±ÞÁõÇÏ´Â ½ÅÈï ½ÃÀåÀÇ ´ë·® Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ °¡Àå ÀûÇÕÇÕ´Ï´Ù. ¶ÇÇÑ, ¼³Æù¾Æ¹Ìµå´Â Á¾Á¾ ¾à¿ë »ç·á³ª ¹°¿¡ È¥ÇÕµÇ¾î ´ë±Ô¸ð °¡Ã౺À̳ª ¹«¸® Àüü¿¡ È¿À²ÀûÀ¸·Î Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ È­ÇÕ¹°µéÀº Áúº´ ºÎ´ãÀ» ÁÙÀÌ°í ½Ä¿ë µ¿¹°ÀÇ »ý»ê¼ºÀ» Çâ»ó½Ã۱â À§ÇÑ ¿¹¹æ À§»ý ÇÁ·Î±×·¥¿¡µµ äÅÃµÇ¾î »ý»êÀÚ¿¡°Ô Á÷Á¢ÀûÀÎ °æÁ¦Àû È¿°ú¸¦ °¡Á®´ÙÁÖ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ó¾÷¿¡¼­ ¼³Æù¾Æ¹ÌµåÀÇ ±¤¹üÀ§ÇÑ »ç¿ëÀº ½Äǰ ³» Ç×»ýÁ¦ ÀÜ·ù ¹× ȯ°æ ¿À¿°¿¡ ´ëÇÑ ¿ì·Á°¡ ³ô¾ÆÁö¸é¼­ ÇöÀç ¸é¹ÐÇÑ Á¶»ç¸¦ ¹Þ°í ÀÖ½À´Ï´Ù. À¯·´¿¬ÇÕ(EU), ¹Ì±¹, Áß±¹ µî °¢ Áö¿ªÀÇ ±ÔÁ¦±â°üÀº ½ÄǰÀÇ ¾ÈÀü¼ºÀ» È®º¸Çϱâ À§ÇØ ÀÜ·ù ¸ð´ÏÅ͸µ ¹× ÃÖ´ëÀÜ·ù±âÁØÄ¡(MRL) Á¦µµ¸¦ µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±ÔÁ¦´Â °ú´Ù »ç¿ëÀ» ¾ïÁ¦ÇÏ´Â ÇÑÆí, ÀÜ·ù¹°ÁúÀ» Æ÷ÇÔÇÏÁö ¾Ê´Â Á¦Á¦ÀÇ ±â¼ú Çõ½Å°ú ¼öÀÇÇÐÀû Áø´Ü ¹æ¹ýÀ» °³¼±ÇÏ¿© Ç¥Àû Ä¡·á¸¦ À¯µµÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ƯÈ÷ ¾Æ½Ã¾Æ¿Í ¾ÆÇÁ¸®Ä«¿¡¼­ Àü ¼¼°è ´Ü¹éÁú ¼Òºñ°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼³Æù ¾Æ¹ÌµåÀÇ µ¿¹°¿ë ÀÀ¿ë ºÐ¾ß´Â °è¼ÓÇØ¼­ ½ÃÀå ¾ÈÁ¤ÀÇ Áß¿äÇÑ ÃËÁøÁ¦°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿À´Ã³¯ ¼³Æù¾Æ¹ÌµåÀÇ ¼¼°è ¼ö¿ä¿Í Àü·«Àû °ü½ÉÀÇ ¿øµ¿·ÂÀº ¹«¾ùÀΰ¡?

¼³Æù¾Æ¹Ìµå ½ÃÀåÀÇ ¼ºÀåÀº Ä¡·á Á¢±Ù¼º, »ê¾÷Àû ¿ä±¸, ¿ªÇÐ ÆÐÅÏ, ºñ¿ë È¿À²¼º°ú °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â °³¹ßµµ»ó±¹ÀÇ ¼¼±Õ¼º °¨¿°ÀÌ Áö¼ÓÀûÀ¸·Î ³ôÀº ºÎ´ãÀ» ¾È°í ÀÖÀ¸¸ç, ¼³Æù¾Æ¹Ìµå´Â Àú·ÅÇÑ °¡°ÝÀ¸·Î ³Î¸® ÀÌ¿ë °¡´ÉÇϱ⠶§¹®¿¡ 1Â÷ ¶Ç´Â 2Â÷ ¼±Åà ¾àǰÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿Í À¯´Ï¼¼ÇÁ(UNICEF)¿Í °°Àº Á¶Á÷ÀÌ Çʼö ÀǾàǰ¿¡ ´ëÇÑ °øÆòÇÑ Á¢±ÙÀ» °­Á¶ÇÏ°Ô µÇ¸é¼­ ¼¼°è º¸°Ç Á¤Ã¥¿¡¼­ ¼³Æù¾Æ¹ÌµåÀÇ ¿ªÇÒÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àα¸ Áõ°¡¿Í µ¿¹°¼º ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ƯÈ÷ ºü¸£°Ô ¹ßÀüÇÏ´Â ½ÅÈï °æÁ¦±¹¿¡¼­ µ¿¹°¿ë Ç×±ÕÁ¦ÀÇ Çʿ伺À» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¼³Æù¾Æ¹Ìµå´Â Á¦Á¶°¡ ºñ±³Àû ¿ëÀÌÇϰí À¯Åë±âÇÑÀÌ ±æ¾î Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷ü¿¡°Ô ¸Å·ÂÀûÀ̸ç, Æø³ÐÀº À¯Åë°ú °æÀï·Â ÀÖ´Â °¡°Ý ¼³Á¤ÀÌ º¸ÀåµË´Ï´Ù. ¿¬±¸ Ãø¸é¿¡¼­´Â ±¸¾àÀÇ Àç»ç¿ëÀÌ ´Ù½Ã ÁÖ¸ñ¹Þ°í ÀÖÀ¸¸ç, ƯÈ÷ ¹«½Ã´çÇÏ´Â ¿­´ë¼º Áúº´°ú ³»¼º º´¿øÃ¼ ¹®Á¦¿¡¼­ ¼³Æù¾Æ¹Ìµå°¡ ´Ù½Ã ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼³Æù¾Æ¹ÌµåÀÇ º´¿ë¿ä¹ý, ¿Ü¿ëÁ¦, ¼Ò¾Æ¿ë Á¦Á¦¿ÍÀÇ ÅëÇÕÀ¸·Î ±× ÀÓ»óÀû Ȱ¿ëµµ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àΰ£°ú µ¿¹°ÀÇ °Ç°­, ±ÔÁ¦ º¯È­, »õ·Î¿î Ä¡·á Àü·« µî ÀÌ·¯ÇÑ ¿ªÇÐÀº ¼³Æù¾Æ¹Ìµå¸¦ Ç×±ÕÁ¦ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ±¸¼º¿ä¼Ò·Î ÀÚ¸® ¸Å±èÇϸ鼭 ¼¼°è ¼ö¿ä¸¦ À¯ÁöÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Åõ¿© °æ·Î(°æ±¸Á¦, ±¹¼ÒÁ¦, ±âŸ), ¿ëµµ(ÇǺΠ°¨¿°Áõ, À§Àå°ü°¨¿°Áõ, ¿ä·Î°¨¿°, È£Èí±â°ü°¨¿°Áõ, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Sulphonamides Market to Reach US$162.5 Million by 2030

The global market for Sulphonamides estimated at US$125.9 Million in the year 2024, is expected to reach US$162.5 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$102.5 Million by the end of the analysis period. Growth in the Topical segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.3 Million While China is Forecast to Grow at 8.0% CAGR

The Sulphonamides market in the U.S. is estimated at US$34.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$33.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Sulphonamides Market - Key Trends & Drivers Summarized

Why Are Sulphonamides Still Relevant in the Era of Advanced Antibiotics?

Despite the emergence of newer classes of antibiotics, sulphonamides remain a foundational element in global antimicrobial therapy, particularly due to their broad-spectrum activity, affordability, and proven clinical history. As some of the earliest synthetic antimicrobials, sulphonamides have been widely used to treat bacterial infections ranging from urinary tract infections and respiratory illnesses to eye infections and meningitis. Their continued relevance stems from both their pharmacological versatility and enduring efficacy against certain strains of bacteria, especially in regions with limited access to newer drugs. Moreover, sulphonamides are commonly used in fixed-dose combinations with other antimicrobials like trimethoprim to enhance therapeutic outcomes and reduce resistance development. Their use is not limited to human medicine-sulphonamides are also critical in veterinary applications, particularly in livestock and poultry, where they help manage bacterial infections and prevent disease outbreaks that could impact food safety. In addition, the cost-effectiveness of sulphonamides makes them an indispensable tool in public health programs, especially in low- and middle-income countries where access to more advanced therapies may be constrained. Their dual application across human and animal health ensures a stable baseline of demand, further underscoring their long-standing utility in global healthcare systems.

How Is Antimicrobial Resistance (AMR) Influencing the Sulphonamides Market?

The global rise in antimicrobial resistance (AMR) is having a dual impact on the sulphonamides market. On one hand, increasing resistance among common pathogens has prompted a re-evaluation of older antibiotics, including sulphonamides, which may still retain effectiveness against specific bacterial strains. In some clinical settings, particularly in resource-limited countries, sulphonamides are being reintroduced into treatment protocols as part of antimicrobial stewardship strategies that rotate or combine therapies to prevent resistance build-up. On the other hand, growing concerns over AMR have led to more stringent regulatory controls on the use of antibiotics in both human and veterinary medicine, influencing how sulphonamides are prescribed and administered. Surveillance programs now require detailed tracking of antibiotic usage, and some countries are moving to restrict or phase out prophylactic use of sulphonamides in agriculture to limit environmental exposure and cross-resistance. However, when used judiciously, sulphonamides remain an important tool in the antimicrobial arsenal. Research into novel formulations and delivery mechanisms-such as targeted drug release and nanoparticle carriers-is also underway to improve efficacy and reduce resistance risks. In this evolving landscape, the market for sulphonamides is being reshaped not by obsolescence, but by the need for controlled, evidence-based applications that align with global AMR mitigation efforts.

What Role Do Veterinary and Agricultural Applications Play in Market Stability?

Veterinary and agricultural uses play a significant role in maintaining the global demand for sulphonamides. In animal health, sulphonamides are widely used to treat bacterial infections in livestock, poultry, and aquaculture, including conditions like coccidiosis, salmonellosis, and respiratory diseases. Their broad-spectrum activity and relatively low cost make them ideal for mass treatment protocols in intensive farming systems, especially in emerging markets where livestock production is increasing rapidly. Moreover, sulphonamides are often included in medicated feed or water, allowing for efficient delivery across large herds or flocks. These compounds are also employed in preventive health programs to reduce disease burden and improve productivity in food animals, which has a direct economic impact for producers. However, the extensive use of sulphonamides in agriculture is now being scrutinized under growing concerns about antibiotic residues in food products and environmental contamination. Regulatory agencies across regions-including the European Union, the United States, and China-have introduced residue monitoring and maximum residue limit (MRL) frameworks to ensure food safety. While such regulations may restrain overuse, they are also prompting innovation in residue-free formulations and improved veterinary diagnostics to guide targeted treatment. As global protein consumption rises, particularly in Asia and Africa, the veterinary application of sulphonamides is expected to remain a key driver of market stability.

What’s Driving Global Demand and Strategic Interest in Sulphonamides Today?

The growth in the sulphonamides market is driven by several factors related to therapeutic access, industrial need, epidemiological patterns, and cost-efficiency. One of the key drivers is the continued high burden of bacterial infections in developing regions, where sulphonamides serve as first-line or second-line therapy due to their affordability and widespread availability. The growing emphasis on equitable access to essential medicines by organizations such as the WHO and UNICEF reinforces the role of sulphonamides in global health policies. Additionally, population growth and the increasing demand for animal protein are expanding the need for veterinary antimicrobials, particularly in fast-developing agricultural economies. The relative ease of manufacturing and long shelf life of sulphonamides make them attractive to generic pharmaceutical producers, ensuring broad distribution and competitive pricing. On the research front, renewed interest in repurposing older drugs has brought sulphonamides back into focus, especially in the context of neglected tropical diseases and resistant pathogens. Furthermore, the integration of sulphonamides into combination therapies, topical treatments, and pediatric formulations is expanding their clinical versatility. Collectively, these dynamics-spanning human and animal health, regulatory shifts, and emerging therapeutic strategies-are sustaining global demand and positioning sulphonamides as an enduring component of the antimicrobial market.

SCOPE OF STUDY:

The report analyzes the Sulphonamides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Topical, Others); Application (Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â